David J. Arthur - 20 Jan 2022 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fac
Issuer symbol
SLRX
Transactions as of
20 Jan 2022
Net transactions value
$0
Form type
4
Filing time
21 Jan 2022, 15:08:11 UTC
Previous filing
05 Nov 2021
Next filing
09 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLRX Stock Option (right to buy) Award $0 +500,000 $0.000000 500,000 20 Jan 2022 Common Stock 500,000 $0.4800 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options are fully vested on January 19, 2023, and 1/36 of the remaining options vest on each monthly anniversary thereafter.